Treating COVID-19 by traditional Chinese medicine: a charming strategy?

• Main Authors: Yu-Liang Zhang, Wan-Ying Zhang, Xin-Zhe Zhao, Jia-Ming Xiong, Guo-Wei Zhang
• Format: Article
• Language: English
• Published: Hong Kong Gold Orchid Science and Technology Co., Limited 2020-06-01
• Series: Traditional Medicine Research
• Subjects: covid-19; traditional chinese medicine
• Online Access: https://www.tmrjournals.com/tmr/EN/10.12032/TMR20200515179
• ISSN: 2413-3973; 2413-3973

On April 14, 2020, the State Council of China announced that “three proprietary Chinese medicines and three decoctions” of effective traditional Chinese medicine (TCM) in the treatment of the novel coronavirus pneumonia have passed clinical practice screenings [1]. Some scholars believe that early TCM intervention of mild and moderate cases and recovery period may reduce the ratio of mild cases progressing into severe and critical cases. Some data have also suggested that the combination of TCM and Western medicine may reduce the mortality rate in severe and critical cases [2, 3]. The “three proprietary Chinese medicines” are Chinese patent drug Jinhua Qinggan granules (approval number of State Food and Drug Administration of China (SFDA) Z20160001), Lianhua Qingwen granules (SFDA approval number Z20100040), and Xuebijing injection (SFDA approval number Z20040033) [4]. In this regard, the National Medical Products Administration of China recently approved the inclusion of the treatment of the novel coronavirus pneumonia as a new indication of the “three proprietary Chinese medicines”, which have become the world’s first batch of drugs suitable for COVID-19 (Table 1) [5]. The “three decoctions” are empirical formula of Chinese medicine Qingfei Paidu decoction, Huashi Baidu decoction, and Xuanfei Baidu decoction (Table 2). Among them, Qingfei Paidu granules and Huashi Baidu granule have been recently approved for clinical trials [5]. Jinhua Qinggan granule is a proprietary Chinese medicine developed during the 2009 H1N1 influenza pandemic. Both Lianhua Qingwen capsule and Xuebijing injection were identified as proprietary Chinese medicines developed and listed during the SARS in 2003 [3–5]. At present, 22 TCM treatment programs have been registered for clinical trials. However, because Lianhua Qingwen capsule contains Houttuynia cordata, Qingfei Paidu decoction contains Belamcandae Rhizoma, and both of them contain aristolochic acid, which can cause kidney injury and liver cancer [6–7]. Xuanfei Baidu decoction and Qingfei Paidu decoction contain Ephedrae Herba, which has cardiovascular toxicity and stimulative effect on central nervous system [8]. Qingfei Paidu decoction contains Alismatis Rhizoma, which may cause kidney injury [9]. Perhaps it is the above toxicity of herb that prohibits the import or clinical application of these six decoctions in Sweden, Singapore, the United States, Canada and other countries [10].